Diagnostics DevelopmentNational facilities
Our national platform for Diagnostics Development (DD) and its Clinical Genomics facilities have been established in Stockholm, Uppsala, Lund and Gothenburg to facilitate the translation of new high-throughput (HTP) techniques, such as next-generation sequencing (NGS), into clinical use. Recently, it was decided that three* new locations will be added: Linköping, Örebro and Umeå. Together, the seven facility nodes form the SciLifeLab Clinical Genomics infrastructure with the overall aim to meet the needs from translational researchers and clinicians in healthcare and public health systems by providing service and support at the national level in order to promote and adapt the use of HTP techniques in routine diagnostics.
HTP technologies have a great potential to impact future set-up for clinical diagnostics, e.g. in diagnostics of cancer, inherited diseases and communicable diseases, since significantly more information can be provided by these technologies for each patient or sample. Nevertheless, HTP technologies often involve complicated work-flows and specialized equipment that generate large amounts of data requiring specialized data analysis before interpretation. Thus, the clinical implementation of these techniques requires careful adaptation to healthcare requirements regarding rapid and secure handling and processing of data as well as accurate interpretation of test results.
To help healthcare and public health systems to overcome these challenges as well as to keep pace with the rapidly developing techniques, this platform integrates technological, bioinformatics and clinical expertise to facilitate the application of HTP genomics in diagnostics. An important aim for the platform is to disseminate up-to-date information about established assays/protocols and hence serve as a national competence center for HTP analysis in collaboration with hospitals and public health organizations throughout the country. A crucial aspect of this work is also to prepare national guidelines and ethical principles for interpretation of test results using these new technologies.
Richard Rosenquist Brandell, Platform Director (Karolinska Institutet)
* The novel Clinical Genomics infrastructure nodes:
Maréne Landström email@example.com
Gisela Helenius firstname.lastname@example.org